Navigation Links
The European Commission Grants Marketing Authorization for DIFICLIR™ (fidaxomicin) Tablets for Treatment of Clostridium difficile Infections
Date:12/12/2011

SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Astellas Pharma Europe Ltd., a European subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) announced today that the European Commission has granted Marketing Authorization (MA) for DIFICLIR™ (fidaxomicin) tablets for the treatment of adults with Clostridium difficile infections (CDI) also known as Clostridium difficile-associated diarrhea (CDAD). CDI is a significant problem in hospitals and long-term care facilities all over the world. EMA approval was based on two large, multi-national, Phase 3 clinical trials that demonstrated that DIFICLIR was as effective as oral vancomycin in treating CDI. DIFICLIR had a significantly lower rate of recurrence (including relapses) compared to vancomycin in the 30 days following treatment.  DIFICLIR is the only drug approved by the EMA proven to significantly lower the rate of recurrence of CDI compared to oral vancomycin. The clinical trials included patients over the age of 65 and those taking concomitant antibiotics to treat multiple infections.

"The European approval is a key step in making fidaxomicin more widely available to patients across the globe to treat this very serious disease," said Pedro Lichtinger, President and Chief Executive Officer of Optimer. "We believe we have obtained a very strong label recognizing the benefits of DIFICLIR versus vancomycin, including significant reductions in recurrence."

The European approval affirms the recent positive opinion from the Committee of Medicinal Products for Human Use (CHMP) and is based on two Phase 3 clinical trials that were conducted to ensure the safety and efficacy of 400mg/day DIFICLIR (fidaxomicin) tablets compared to 500mg/day oral vancomycin for 10 days in subjects with CDI. The first Phase 3 study was carried out in 629 subjects in No
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ULURU Inc. Extends the European Altrazeal® License to Include Australia and New Zealand
2. Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™
3. Avanafil Data Presented at the European Society of Sexual Medicine Meeting
4. European Medicines Agencys (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012
5. CardioInsight Announces CE Mark Clearance and European Launch of the ECVUE™ Non-Invasive Electrocardiographic Mapping System
6. Omeros Announces Submission to European Medicines Agency of Paediatric Investigation Plan Letter of Intent for OMS302
7. Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union
8. X-ray Equipment - Top 5 European Markets
9. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
10. RSB Spine, LLC, Announces European Patent Allowance
11. Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Hospira, Inc. (NYSE: ... of biosimilar therapies, spoke about the importance of extrapolation ... Generics Association (EGA) annual European Biosimilars Group conference in ... also announced the publication of a pivotal white paper ... full promise of biosimilars." Speaking at ...
(Date:4/24/2015)... Mass. , April 24, 2015  Blueprint ... BLU-554, a selective and potent inhibitor of fibroblast ... activity in models of hepatocellular carcinoma (HCC) that ... therapeutic candidate, BLU-554 induced complete tumor regression in ... an FGFR4-activating ligand at the highest dose levels. ...
(Date:4/23/2015)... IRVINE, Calif., April 23, 2015  Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, today reported net ... million, or $1.12 per diluted share.  Net income for ... or $0.56 per diluted share, and non-GAAP net income ... Net sales for the quarter ended March 31, 2015 ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
...  Reportlinker.com announces that a new market ... catalogue: Triple Analysis: ... http://www.reportlinker.com/p0284888/Triple-Analysis-Apoptosis-Cancer-Vaccines-and-Antibodies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This ... development strategies by the two mechanism/target/effect ...
... Research Institute (IDRI) announces today that GlaxoSmithKline (GSK) Biologicals ... equipment that will assist IDRI as it designs and ... the developing world. IDRI will apply the gift as ... tuberculosis, leishmaniasis, malaria, leprosy, and pandemic influenza. ...
Cached Medicine Technology:Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 2Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 3Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 4Triple Analysis: Apoptosis, Cancer Vaccines and Antibodies 5GlaxoSmithKline Donates Scientific Equipment to Advance IDRI's Global Health Mission 2
(Date:4/25/2015)... New Jersey (PRWEB) April 25, 2015 ... people aged twelve and above needed treatment for an ... according to the Substance Abuse and Mental Health Services ... September 2011). Beyond these alarming numbers are harrowing stories ... by substance abuse . David H. Kerr ...
(Date:4/25/2015)... April 25, 2015 The federal ... mesh lawsuits filed against C.R. Bard, Inc. continues ... Southern District of West Virginia. According to a ... was convened that day, after certain defendants submitted ... Complaint. The Order directed that any Preliminary Motions ...
(Date:4/25/2015)... Carinsurancequotesinfo.com has released a new blog post that ... for flatbed trucks. , Flatbed trucks are ... They are mainly used for commercial purposes and thus ... explains that by comparing multiple offers, drivers can find ... vehicles. , It is now possible to compare free ...
(Date:4/25/2015)... By definition, a CIO’s responsibility is to support the ... their judgement and expertise to keep digital assets and environments ... article published in National Mortgage News on April 22nd, 2015 ... to their responsibilities by focusing too heavily on making sure ... it comes to company policy and industry best practices, and ...
(Date:4/25/2015)... The impact of the Trivedi Master ... of the public and is likely to cause further, ... and June. From March 21st to March 31st, ... "Special Prayers." More than 600 people participated in the ... and have reported intense experiences that they attest have ...
Breaking Medicine News(10 mins):Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Auto Insurance Quotes for Flatbed Trucks Available Online! 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3
... The following is a,statement of SEIU spokesperson Andrew McDonald:, ... health and,vitality of any democratic organization., "For the last ... and full debate over the future of our union. For ... been the subject of,an even more vigorous debate -- in ...
... China, April 8, 2008 /Xinhua-PRNewswire-FirstCall/ --,Linkwell Corporation (Linkwell ... developer, manufacturer and distributor of healthcare related,disinfectants in ... year-end,financial results in a conference call on Wednesday, ... Company will release its 2007 year-end financial results ...
... rising on,everything from bread to education, and health care is ... a Medicaid patient in the home, the,urgent need for an ... to nurses and other home care advocates,visiting legislators today as ... cost of a nurse,s visit to a home care patient ...
... Mark your calendars for these,training and networking ... Detroit Chapter (IABC/Detroit)!, April 16 Luncheon Session: ... organization,s message impact its market,share? Find out when ... messaging has impacted today,s marketing landscape., Join ...
... School of Medicine and colleagues at Merck Serono Research ... receptor sites on some tumors in different places at ... combination therapy for certain types of cancer. , An ... called epidermal growth factor receptors (EGFR) sitting on their ...
... Newborns Vulnerable for Rare,Metabolic Conditions, WASHINGTON, April 8, ... the Bills to four consecutive Super,Bowls, will be on ... with,Members of Congress asking them to approve and fund ... also participate in a press event with Senators Christopher,Dodd ...
Cached Medicine News:Health News:Linkwell Corporation Year-End 2007 Earnings Release and Conference Call Notice 2Health News:Bayada Nurses Advocates for Increase in Medicaid Reimbursement Rate to Allow More Individuals to Receive Home Care and Hire More Skilled Staff 2Health News:IABC/Detroit Announces April Professional Development and Networking Events 2Health News:Double binding sites on tumor target may provide future combination therapy 2Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 2Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 3Health News:Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act 4
The Finstrip combines high performance and flexibility with reliability, simplicity and ease of use....
... PW 384 has set a standard for ... plates. The instrument not only processes all ... washing to further boost wash performance. This ... short wash times as no transport steps ...
... Bio-Rad's Model 1575 immunowash ... control of needle position ... routines and maximize wash ... a large choice of ...
... a powerful, compact and programmable 8-channel ... dispensing pumps. Dispense and aspirate head ... horizontal needle positioning in the well. ... waste bottles and vacuum sensing allow ...
Medicine Products: